Progenics Pharmaceuticals (FRA:PGP) Short-Term Debt : €6.55 Mil (As of Mar. 2020)

View and export this data going back to 1997. Start your Free Trial

What is Progenics Pharmaceuticals Short-Term Debt?

Progenics Pharmaceuticals's Short-Term Debt for the quarter that ended in Mar. 2020 was €6.55 Mil.

Progenics Pharmaceuticals's quarterly Short-Term Debt increased from Sep. 2019 (€5.85 Mil) to Dec. 2019 (€6.41 Mil) and increased from Dec. 2019 (€6.41 Mil) to Mar. 2020 (€6.55 Mil).

Progenics Pharmaceuticals's annual Short-Term Debt increased from Dec. 2017 (€2.07 Mil) to Dec. 2018 (€4.76 Mil) and increased from Dec. 2018 (€4.76 Mil) to Dec. 2019 (€6.41 Mil).

Progenics Pharmaceuticals Short-Term Debt Historical Data

The historical data trend for Progenics Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progenics Pharmaceuticals Short-Term Debt Chart

Progenics Pharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Short-Term Debt

Get a 7-Day Free Trial

2.07

4.76

6.41

Progenics Pharmaceuticals Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Short-Term Debt	Get a 7-Day Free Trial															5.37	5.14	5.85	6.41	6.55

Progenics Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Progenics Pharmaceuticals Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Progenics Pharmaceuticals's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Progenics Pharmaceuticals (FRA:PGP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progenics Pharmaceuticals Inc (FRA:PGP) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

One World Trade Center, Suite J, 47th Floor, New York, NY, USA, 10007

Website

http://www.progenics.com

Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

Progenics Pharmaceuticals (FRA:PGP) Headlines

From GuruFocus

PGP Statement on SEC Settlement

By sperokesalga sperokesalga • 06-16-2023